Cargando…

Is It Possible to Prevent Ovarian Hyperstimulation Syndrome by Gonadotropin-Releasing Hormone Agonist Triggering and Modified Luteal Support in Patients With Polycystic Ovarian Morphology?

BACKGROUND: Gonadotropin-releasing hormone (GnRH) agonist triggering plus 1,500 IU human chorionic gonadotropin (hCG) supplementation protocol was previously claimed effective in reducing the ovarian hyperstimulation syndrome (OHSS) incidence in high responders. METHODS: This retrospective study inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gurbuz, Ali Sami, Deveer, Ruya, Kucuk, Mert, Ozcimen, Necati, Incesu, Dilek, Koseoglu, Sezen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817580/ https://www.ncbi.nlm.nih.gov/pubmed/27081426 http://dx.doi.org/10.14740/jocmr2500w

Ejemplares similares

Severe ovarian hyperstimulation syndrome and gonadotropin-releasing hormone agonist trigger in patients with hypogonadotropic hypogonadism: A report of two cases
por: Gürbüz, Ali Sami, et al.
Publicado: (2020)

Chorionic gonadotropin: Ovarian hyperstimulation syndrome: case report
Publicado: (2021)

The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome
por: Chappell, Neil, et al.
Publicado: (2017)

Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review
por: Ingold, Caroline, et al.
Publicado: (2023)

Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study
por: Iliodromiti, Stamatina, et al.
Publicado: (2013)

Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation
por: O’Brien, Travis J, et al.
Publicado: (2013)

GnRH agonist triggering affects the kinetics of embryo development: a comparative study
por: Gurbuz, Ali Sami, et al.
Publicado: (2016)

Persistent ascites resolving with gonadotropin-releasing-hormone-agonist 18 months after hospitalization for severe ovarian hyperstimulation syndrome
por: Comba, Cihan, et al.
Publicado: (2013)

Serum Copeptin, Pentraxin 3, Anti-Mullerian Hormone Levels With Echocardiography and Carotid Artery Intima-Media Thickness in Adolescents With Polycystic Ovary Syndrome
por: Deveer, Mehmet, et al.
Publicado: (2015)

Changes in Coagulation and Fibrinolytic Indices in Women with Polycystic Ovarian Syndrome Undergoing Controlled Ovarian Hyperstimulation
por: Huang, Ying, et al.
Publicado: (2014)

Ovarian hyperstimulation syndrome
por: Kumar, Pratap, et al.
Publicado: (2011)

Ovarian and intellectual hyperstimulation
por: Quaas, Alexander M.
Publicado: (2021)

Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome: A controlled clinical study
por: WANG, YA-QIN, et al.
Publicado: (2014)

Correlation between saliva and serum concentrations of estradiol in women undergoing ovarian hyperstimulation with gonadotropins for IVF/ICSI
por: Dielen, C, et al.
Publicado: (2017)

A Retrospective Study of Letrozole Treatment Prior to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome Undergoing In Vitro Fertilization at Risk of Ovarian Hyperstimulation Syndrome
por: Chen, Yilu, et al.
Publicado: (2018)

Pregnancy Rate Following Luteal Phase Support in Iranian Women with Polycystic Ovarian Syndrome
por: Foroozanfard, Fatemeh, et al.
Publicado: (2014)

A proteomic analysis identifies candidate early biomarkers to predict ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients
por: Wu, Lan, et al.
Publicado: (2017)

Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis
por: Mahajan, Nalini, et al.
Publicado: (2015)

Luteal phase ovarian stimulation for poor ovarian responders
por: Zhang, Wei, et al.
Publicado: (2018)

Non-Invasive Isthmocele Treatment: A New Therapeutic Option During Assisted Reproductive Technology Cycles?
por: Gurbuz, Ali Sami, et al.
Publicado: (2020)

Ovarian Hyperstimulation Syndrome, the Master of Disguise?
por: Ironside, Emily Charlotte, et al.
Publicado: (2015)

Nomogram Model to Predict the Probability of Ovarian Hyperstimulation Syndrome in the Treatment of Patients With Polycystic Ovary Syndrome
por: Li, Fei, et al.
Publicado: (2021)

Persistent megalocystic ovaries after ovarian hyperstimulation syndrome in a postpartum patient with polycystic ovarian syndrome: a case report
por: Shi, Jinghua, et al.
Publicado: (2018)

The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments
por: Zhu, Xiuxian, et al.
Publicado: (2016)

Antral follicle count and anti-Müllerian hormone level as predictors of ovarian hyperstimulation syndrome in women with polycystic ovarian syndrome undergoing controlled ovarian stimulation
por: Izhar, Rubina, et al.
Publicado: (2021)

Natural autoantibodies to the gonadotropin-releasing hormone receptor in polycystic ovarian syndrome
por: Sattler, Lisa-Marie, et al.
Publicado: (2021)

Evaluation of the impact of gonadotropin-releasing hormone agonist as an adjuvant in luteal-phase support on IVF outcome
por: Inamdar, Dattaprasad B, et al.
Publicado: (2012)

Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series
por: Lee, Dayong, et al.
Publicado: (2017)

Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients
por: Martazanova, Bella, et al.
Publicado: (2022)

Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome – a prospective randomized double-blind clinical trial
por: Engmann, L. L., et al.
Publicado: (2019)

Ovarian cyst regression with levothyroxine in ovarian hyperstimulation syndrome associated with hypothyroidism
por: Langroudi, Roghieh Molaei, et al.
Publicado: (2013)

The effect of controlled ovarian hyperstimulation on ovarian reserve via PTEN pathway
por: Sezginer, Perihan, et al.
Publicado: (2022)

The Effectiveness of Cabergoline for the Prevention of Ovarian Hyperstimulation Syndrome
por: Hosseini, Marzieh Agha, et al.
Publicado: (2011)

Ovarian Hyperstimulation Syndrome as an Etiology of Obstructive Uropathy
por: Marak, Creticus P., et al.
Publicado: (2013)

Radiological Illustration of Spontaneous Ovarian Hyperstimulation Syndrome
por: Mittal, Kartik, et al.
Publicado: (2015)

Prevention of Ovarian Hyperstimulation Syndrome: A Review
por: Smith, Vinayak, et al.
Publicado: (2015)

Zika virus during controlled ovarian hyperstimulation
por: Joob, Beuy, et al.
Publicado: (2019)

Immunoglobulin Treatment in Severe Ovarian Hyperstimulation Syndrome
por: Gómez, Gemma Grau, et al.
Publicado: (2019)

Ovarian Hyper-Response to Administration of an GnRH-Agonist Without Gonadotropins
por: Park, Hyun Tae, et al.
Publicado: (2011)

Gonadotropin-releasing hormone agonist for ovulation trigger – OHSS prevention and use of modified luteal phase support for fresh embryo transfer
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_of7l8gr4a0h6f2pv3jokjta6jr